Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole is the recommended first line treatment of invasive aspergillosis. More recently, isavuconazole appeared to be not less effective than voriconazole in the treatment of filamentous IFI, with a better tolerance profile. The investigators aim to evaluate better the efficacy and the safety of isavuconazole in the treatment of cerebral aspergillosis by a descriptive, multicentric, international retrospective cohort study.
• Proven or probable cerebral aspergillosis according to the EORTC criteria modified by adding diabetes in the host criteria
• In child or adult
• Treated by isavuconazole at least 7 days
• Diagnosed between March 2017 and June 2020
This content was sourced from clinicaltrials.gov